Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

5.42
-0.0900-1.63%
Post-market: 5.23-0.1900-3.51%19:13 EDT
Volume:130.32K
Turnover:745.15K
Market Cap:46.67M
PE:-1.54
High:6.09
Open:5.57
Low:5.40
Close:5.51
52wk High:19.35
52wk Low:3.76
Shares:8.61M
Float Shares:8.61M
Volume Ratio:1.72
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5221
EPS(LYR):-3.0396
ROE:-48.89%
ROA:-29.87%
PB:0.94
PE(LYR):-1.78

Loading ...

Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS

Reuters
·
Oct 21, 2025

Health Rounds: Scientists find way to make breast cancer drug work better for younger women

Reuters
·
Oct 17, 2025

Atossa Therapeutics appoints Mark Daniel as CFO

TIPRANKS
·
Oct 14, 2025

Atossa Appoints Mark Daniel, Cpa, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

THOMSON REUTERS
·
Oct 14, 2025

BRIEF-Atossa Therapeutics - Appoints Mark Daniel As CFO - SEC Filing

Reuters
·
Oct 14, 2025

Atossa Therapeutics - Heather Rees Steps Down as CFO, Assists Transition Until Nov 15 - SEC Filing

THOMSON REUTERS
·
Oct 14, 2025

Atossa Therapeutics Appoints Mark Daniel as Chief Financial Officer to Lead Commercial Readiness

Reuters
·
Oct 14, 2025

Atossa Therapeutics Granted Israeli Patent for High-Purity Z-Endoxifen Formulations

Reuters
·
Oct 13, 2025

BRIEF-Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities

Reuters
·
Oct 06, 2025

Atossa Therapeutics - No Change to Patient Safety Data Collection or Data Safety Monitoring Committee Oversight by This Amendment

THOMSON REUTERS
·
Oct 06, 2025

Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial to Prioritize for 2026 Nda-Enabling Activities

THOMSON REUTERS
·
Oct 06, 2025

Atossa Therapeutics Inc - Focuses on Nda-Enabling Activities for Investigational (Z)-Endoxifen in 2026

THOMSON REUTERS
·
Oct 06, 2025

Atossa Therapeutics Inc - Evangeline Study Patient Total Reduced to 40-65

THOMSON REUTERS
·
Oct 06, 2025

Atossa Therapeutics Inc - Changes Expected to Reduce Study Costs and Accelerate Readouts

THOMSON REUTERS
·
Oct 06, 2025

Atossa Therapeutics Appoints Janet R. Rea as Senior Vice President of R&D to Accelerate (Z)-Endoxifen Toward Regulatory Milestones

Reuters
·
Oct 01, 2025